Croban’s AbbVie ABBV Stock Holding History

Croban’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.78M	Buy	7,077 +172	+2%	+$37K	0.78%	33
2026 Q1	$1.5M	Buy	6,905 +47	+0.7%	+$10.4K	0.71%	39
2025 Q4	$1.57M	Buy	6,858 +74	+1%	+$16.9K	0.76%	35
2025 Q3	$1.57M	Sell	6,784 -88	-1%	-$17.9K	1.05%	35
2025 Q2	$1.28M	Buy	6,872 +8	+0.1%	+$1.49K	1.09%	37
2025 Q1	$1.44M	Sell	6,864 -220	-3%	-$42.8K	1.32%	22
2024 Q4	$1.26M	Buy	+7,084	New	+$1.3M	1.24%	27
2023 Q4	$1.26M	Buy	+7,084	New	+$1.03M	1.25%	27

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Croban's ABBV Position: Q2 2026 in Review

Croban increased its AbbVie (ABBV) stake by 2.5% in Q2 2026, buying an estimated $37K and bringing the position to 7,077 shares worth $1.78M. The position accounts for 0.78% of the portfolio, ranked #33.

Croban first reported a position in ABBV in Q4 2023 and has held it in 8 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Croban held 7,077 shares of AbbVie worth $1.78M as of Q2 2026.
Croban bought 172 AbbVie shares in Q2 2026, an estimated $37K.
AbbVie made up 0.78% of Croban's portfolio in Q2 2026, its #33 holding.
Croban first reported a position in AbbVie in Q4 2023 and has held it in 8 quarters since.
4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Croban's 13F filing for Q2 2026, filed 3 Aug 2026.